CEBP Candidate Pathways, Whole Genome Scans: Reconciling Results, Looking into the Future Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Published online first on May 7, 2008
[Cancer Epidemiology Biomarkers & Prevention, 10.1158/1055-9965.EPI-08-0118]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ford, M. E.
Right arrow Articles by Lamerato, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, M. E.
Right arrow Articles by Lamerato, L.

Research Articles

Effects of Baseline Comorbidities on Cancer Screening Trial Adherence among Older African American Men

Marvella E. Ford 1*, Suzanne L. Havstad , Maya E. Fields , Brandy Manigo , Beth McClary , Lois Lamerato

1 1Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina; 2Department of Health Sciences, South Carolina State University, Orangeburg, South Carolina; and 3Department of Biostatistics and Research Epidemiology and 4Ford Cancer Center, Henry Ford Health Sciences Center, Detroit, Michigan

* To whom correspondence should be addressed. E-mail: fordmar{at}musc.edu.


   Abstract

Background: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages ≥55 years) enrolled in a case management intervention in a cancer screening trial.

Methods: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n = 344) or to a case management control group (n = 339). The effects of comorbidities on the screening adherence rates of each group were then assessed.

Results: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate-specific antigen test (P = 0.02) and the digital rectal examination for prostate cancer screening (P = 0.01), to the chest X-ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P = 0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X-ray (P = 0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P = 0.05).

Conclusions: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening. (Cancer Epidemiol Biomarkers Prev 2008;17(5):1234–9)

Key Words: African American, Males, Cancer, Screening, Comorbidities







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.